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with (INH; intraperitoneally significant
when it was injected before or after a lethal intravenous challenge with endotoxin. The INH preparation used
was not contaminated with endotoxin. Tumor necrosis factor (TNF) was not elevated in sera from NMRI mice
2 h after the injection of INH. INH did not influence TNF synthesis or release determined in human monocytes
in vitro. Therefore, it is concluded that the protective effect of INH against lethal endotoxin is not due to a
suppressive effect of INH on TNF production.
Silverstein and colleagues (11) recently reported that
hydrazine sulfate pretreatment of mice results in a significant
protection against a subsequent lethal endotoxin challenge,
while more fatalities were obtained with injection after the
endotoxin challenge. The authors suggested that the protec-
tive effect might be due to the prevention of the drop in the
hepatic phosphoenolpyruvate carboxykinase, although no
improvement in plasma glucose was observed. In this con-
text, the interference of hydrazine with tumor necrosis
factor (TNF) also was discussed. While TNF has been
shown to be an important mediator of the lethal effects of
endotoxin (4, 12), it was demonstrated that small concentra-
tions of TNF mediate the beneficial effects of endotoxin,
such as endotoxin tolerance (6) and radioprotection and
stimulation of hematopoiesis (14). Therefore, it was of
interest to study whether the protection elicited by hydra-
zine (11) may be due to a release of TNF. In the study
described here, isoniazid (INH), a precursor of hydrazine
sulfate, was used.
INH together with rifampin is one of the most potent
antituberculosis drugs (1). The major pathway of INH me-
tabolism is acetylation, which leads, via acetylisoniazid, to
isonicotinic acid; cleavage of acetylisoniazid in the human
body (5) and in mice (9) results also in the formation of
monoacetylhydrazine, an important determinant of the hep-
atotoxicity of INH. A substantial fraction of the acetylhy-
drazine passes through a pathway that has been shown to
generate in animals highly reactive and hepatotoxic interme-
diates by the cytochrome P-450 monooxygenase system (9).
Up to 14 ng of hydrazine ml-' was detected in the sera of
healthy male volunteers receiving INH (300 mg) and ri-
fampin (600 mg) daily for 15 days (3). Because of the
different pharmacokinetics of INH in mice compared with
those in humans, a relative high dosage of 25 mg/kg of body
weight is required in mice, which corresponds roughly to 5
mg of INH per kg in humans (7).
Ten female NMRI mice (age, 11 to 12 weeks; Zentralin-
stitut fur Versuchstiere, Hannover, Federal Republic of
Germany) per group were injected intraperitoneally (i.p.)
with 25 mg of INH per kg of body weight at different times,
as indicated in Fig. 1, before or after a lethal intravenous
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(i.v.) challenge with 150 p.g of endotoxin. The endotoxin was
extracted from Escherichia coli 0111 by the Boivin tri-
chloroacetic acid method. The mice were not fasted before
or during the experiment. The 50%6 lethal dose of the
preparation used in these experiments was <125 pug per
mouse. In former experiments studying the protective effect
of a thromboxane A receptor blocker (15), it was found that
saline injection of the control groups of mice at the different
times of treatment did not change the lethality rate following
endotoxin challenge compared with the lethality rate in
untreated controls; therefore, a saline-treated control group
was not used in the present study, to avoid the unnecessary
use of additional groups of control mice.
In the first experiment, 25 mg of INH per kg was injected
i.p. into 10 mice 5 h before (-5 h) the i.v. challenge with 125
,ug of endotoxin. No significant protection resulted in this
experiment; within 1 day, 60% of the nonpretreated control
group of 10 mice died and 30% of the pretreated mice died.
In both groups, no additional deaths occurred until the end
of the observation period (day 5). These results are in
contrast to those described by Silverstein et al. (11), in which
protection was induced when hydrazine was given 5 h before
the lethal challenge with endotoxin. In those experiments,
the mice were fasted and a different endotoxin preparation
was used. However, a statistically significant delay in the
onset of death in all groups treated and a reduction in
lethality rate following treatment at -1 h or +2 h was
observed, as indicated in Fig. 1. INH (25 mg) failed to
produce protection when it was given at -24 h; however,
when 50 mg of INH per kg was injected 24 h before the
challenge with endotoxin, the profile of the lethality rate was
identical to that shown in Fig. 1 for the pretreatment at -1 h.
The protection of mice to a lethal challenge with endotoxin
induced by INH differs from the endotoxin tolerance-induc-
ing capacity of small doses of endotoxin or its mediators. It
is well known that minute doses of endotoxin are only potent
inducers of endotoxin tolerance when animals are pretreated
-24 h before the injection of toxic endotoxin concentrations.
Endotoxin injected in small doses shortly before or after the
lethal challenge has no protective effect. TNF enhanced the
lethality rate when it was injected simultaneously with cecal
ligation and puncture, resulting in severe septicemia (16).
Since small amounts of endotoxin (5 ng) are capable of
inducing endotoxin tolerance in mice when it is injected 24 h
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FIG. 1. Protection against endotoxin-induced lethality by INH in
NMRI mice (n = 10 mice per group). INH (25 mg/kg) was injected
i.p. into mice 24 h (0), or 1 h (R) before and 2 h (l) after a lethal i.v.
challenge with 150 ,ug of trichloroacetic acid endotoxin from E. coli
0111 (control; 0); mice were pretreated i.p. with 50 mg of INH per
kg 24 h before the endotoxin challenge (G). a, P < 0.05; b, P < 0.01
compared with the nontreated controls (chi-square test).
before the lethal challenge (17), the concentration of INH
used in these experiments (Saarstickstoff-Fatol) was tested
for contamination with endotoxin. By using an automatic
kinetic turbidimetric Limulus amebocyte lysate (LAL) mi-
crotiter test developed in our laboratory (13), no LAL
activity was detectable. In addition, INH interference with
the endotoxin-LAL reaction also was excluded.
In order to determine TNF levels after INH injection,
female NMRI mice (age, 11 to 12 weeks) were injected i.p.
with 25 mg of INH per kg of body weight. Two hours after
the injection of INH, these mice and an untreated control
group (n = 6 mice per group) were bled by orbital puncture,
and the sera were stored at -20°C until they were assayed
individually. In these sera, TNF levels were determined in a
TNF cytotoxicity assay by using L929 cells (10). The sensi-
tivity of this assay is 0.5 ng of TNF per ml. TNF was not
measurable in any of the sera from either group tested.
Recently, it was demonstrated that antibiotics, in addition
to their potent antimicrobial activity, also elicit immunomod-
ulatory effects. Ciprofloxacin, for instance, was shown to
suppress TNF production by human monocytes (2). In order
to test whether INH influences TNF synthesis and produc-
tion, TNF mRNA expression was measured in cultured
human monocytes treated with 2, 10, or 50 ,ug of INH after
2 h by using dot blot or Northern blot techniques (8). TNF
production was measured in supernatants of identical cul-
tures after 16 h in the bioassay or by enzyme-linked immuno-
sorbent assay (10). In the same way, the influence ofINH on
the capacity of Staphylococcus aureus, in contrast to lipo-
polysaccharide, a very potent stimulator ofTNF production
in human monocytes (10), to increase TNF mRNA was
determined. In all experiments performed, INH did not
influence TNF mRNA expression, per se, or S. aureus-
stimulated TNF mRNA expression (Fig. 2). S. aureus-
induced values of soluble TNF were 2.95 ± 0.21 ng/ml,
which were unchanged in the presence of INH. The TNF
levels were 2.78 ± 0.52 ng/ml (2 ,ug of INH), 2.54 ± 0.35
ng/ml (10 pg of INH), and 2.41 ± 0.14 ng/ml (50 Lg of INH).
Thus, the capacity ofINH to exert protection against a lethal
endotoxin challenge under the experimental conditions de-
FIG. 2. TNF mRNA expression in human monocytes. Cytoplas-
mic RNA from the adherent fraction of 4 x 10' peripheral blood
mononuclear cells cultured without stimulus (lanes 1 to 4) or with S.
aureus (10 ,ug/ml; lanes 5 to 8) in the absence (lanes 1 and 5) or in the
presence of 2 ,Lg of INH per ml (lanes 2 and 6) 10 Fig of INH per ml
(lanes 3 and 7), or 50 Itg of INH per ml (lanes 4 and 8) was blotted
in serial 102 dilutions from top to bottom and was hybridized with
a TNF cDNA probe.
scribed here is not due to a suppressive effect of INH on
TNF production. Further experiments are necessary to
elucidate the mechanisms involved in the enhancement of
nonspecific resistance by INH.
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